Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape

Jane De Lartigue, PhD
Published: Tuesday, Jul 02, 2019
Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

Historically, assigning clinical actionability to oncogenic drivers has focused on the somatic mutations unique to cancer cells. Germline mutations contained within the heritable genome have been largely consigned to heritable cancer risk management.

Table. Gene Mutations Targeted by FDA-Approved Companion Diagnosticsa9

TABLE. GENE MUTATIONS TARGETED BY FDA-APPROVED COMPANION DIAGNOSTICSa9 Now, genome sequencing study findings are fostering a growing appreciation of both the burden of germline mutations and their potential clinical actionability. Furthermore, in both germline and tumor genomes, specific mutations have been identified in discordant histological cancer types. Pan-Cancer analyses have also revealed genetic interactions between germline and somatic mutations, suggesting that the germline genome may have a significant impact on the somatic evolution of the tumor.4-6
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x